Revvity Inc

RVTY: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$199.00NyxzmzGqwplydw

PerkinElmer Raises 2021 Outlook After Strong Q2 and Announces BioLegend Acquisition; Raising FVE

Narrow-moat PerkinElmer reported strong second-quarter results that beat expectations, and management raised its outlook for 2021 again. On recently generated cash flows and strong near- and long-term prospects, we're raising our fair value estimate to $131 per share from $106 previously. Our new fair value incorporates the planned BioLegend acquisition that was also announced July 26 but still remains below market prices.

Sponsor Center